European urology最新文献

{"title":"Reply to Francesco Montorsi, Francesco Montorsi, Pietro Scilipoti, Alessandro Viti, Alfonso Santangelo, Giuseppe Rosiello, and Marco Moschini’s Letter to the Editor re: Jeremy Yuen-Chun Teoh, Cheung-Hing Cheng, Chiu-Fung Tsang, et al. Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial. Eur Urol. 2024;86:103–111","authors":"Jeremy Yuen-Chun Teoh , Peter Ka-Fung Chiu , Chi-Hang Yee , Chi-Fai Ng","doi":"10.1016/j.eururo.2024.07.005","DOIUrl":"10.1016/j.eururo.2024.07.005","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Page e118"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Detection of Recurrence Through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study","authors":"Christian D. Fankhauser , Richard Cathomas , Silke Gillessen , Christian Rothermundt","doi":"10.1016/j.eururo.2024.04.018","DOIUrl":"10.1016/j.eururo.2024.04.018","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Pages 477-478"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140913602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effective Prostate-specific Antigen Screening: Who Do We Screen and What Treatments Do We Offer?","authors":"Peter C. Albertsen","doi":"10.1016/j.eururo.2024.05.023","DOIUrl":"10.1016/j.eururo.2024.05.023","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Pages 409-410"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Carlotta Nedbal, Patrick Juliebø-Jones, Eamonn Rogers, et al. Improving Patient Information and Enhanced Consent in Urology: The Impact of Simulation and Multimedia Tools. A Systematic Literature Review from the European Association of Urology Patient Office. Eur Urol. 2024;86:457–469","authors":"Sandra P. García Nader, Cesar A. Díaz Ritter, Valentina Garcia Perez","doi":"10.1016/j.eururo.2024.07.028","DOIUrl":"10.1016/j.eururo.2024.07.028","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Page e123"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142038020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial","authors":"Lars Boesen , Brian F Chapin","doi":"10.1016/j.eururo.2024.06.012","DOIUrl":"10.1016/j.eururo.2024.06.012","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Pages 479-480"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-derived Models: A Promising Frontier in Testing the Efficacy of Drugs for Bladder Cancer","authors":"Henning Plage , Franz F. Dressler , Annika Fendler","doi":"10.1016/j.eururo.2024.08.020","DOIUrl":"10.1016/j.eururo.2024.08.020","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Pages 445-446"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study","authors":"Roberto Iacovelli ,&nbsp;Chiara Ciccarese ,&nbsp;Sebastiano Buti ,&nbsp;Paolo Andrea Zucali ,&nbsp;Emanuela Fantinel ,&nbsp;Davide Bimbatti ,&nbsp;Elena Verzoni ,&nbsp;Caterina Accettura ,&nbsp;Lucia Bonomi ,&nbsp;Consuelo Buttigliero ,&nbsp;Giuseppe Fornarini ,&nbsp;Stefania Pipitone ,&nbsp;Francesco Atzori ,&nbsp;Cristina Masini ,&nbsp;Francesco Massari ,&nbsp;Francesca Primi ,&nbsp;Alessandro Strusi ,&nbsp;Giulia Claire Giudice ,&nbsp;Matteo Perrino ,&nbsp;Marco Maruzzo ,&nbsp;Giampaolo Tortora","doi":"10.1016/j.eururo.2024.02.014","DOIUrl":"10.1016/j.eururo.2024.02.014","url":null,"abstract":"<div><h3>Background and Objective</h3><div>Combinations of VEGFR-TKIs plus ICI against PD1/PD-L1 are the standard first-line therapy for patients with mRCC, irrespective of the prognostic class. This study aims to investigate the feasibility and safety of withdrawing the VEGFR-TKI but continuing the anti- PD1/PD-L1 in patients who achieve response to their combination.</div></div><div><h3>Methods</h3><div>This was a single-arm phase 2 trial in patients with treatment naïve mRCC with prior nephrectomy, without symptomatic/bulky disease and no liver metastases. Enrolled patients received axitinib+avelumab, after 36 weeks of therapy those who achieved tumor response interrupted axitinib and continued avelumab maintenance until disease progression. The primary endpoint was the rate of patients without progression eight weeks after the axitinib interruption. Secondary endpoints were the median value for progression free (mPFS) and overall survival (mOS) and the safety in the overall population.</div></div><div><h3>Key Findings and Limitations</h3><div>79 patients were enrolled and 75 evaluated for efficacy. A total of 29 (38%) patients had axitinib withdrawn, as per the study design, with 72% of them having no progression after eight weeks and thus achieving the primary endpoint. The mPFS of the overall population was 24 months while the mOS was not reached. The ORR was 76% (12% CR, 64% PR), with 19% of patients having stable disease. In the patients who discontinued axitinib, the incidence of AEs of any grade was 59% and 3% for grade 3 or 4. This study was limited by the lack of the comparative arm.</div></div><div><h3>Conclusions and Clinical Implications</h3><div>The TIDE-A study demonstrates that the withdrawal of VEGFR-TKI with ICI maintenance is feasible for selected mRCC patients with evidence of response to the VEGFR-TKI+ICI combination employed in first-line therapy. Axitinib interruption with avelumab maintenance led to decreased side effects and should be further investigated as a new strategy to delay tumor progression.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Pages 411-419"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe","authors":"Pieter Vynckier ,&nbsp;Lieven Annemans ,&nbsp;Sarah Raes ,&nbsp;Cheïma Amrouch ,&nbsp;Peter Lindgren ,&nbsp;Ondřej Májek ,&nbsp;Katharina Beyer ,&nbsp;Renée C.A. Leenen ,&nbsp;Lionne D.F. Venderbos ,&nbsp;Frederique Denijs ,&nbsp;Meike J. van Harten ,&nbsp;Jozien Helleman ,&nbsp;Renata Chloupková ,&nbsp;Erik Briers ,&nbsp;Vera Vasilyeva ,&nbsp;Juan Gomez Rivas ,&nbsp;Partha Basu ,&nbsp;Arunah Chandran ,&nbsp;Roderick C.N. van den Bergh ,&nbsp;Sarah Collen ,&nbsp;Lisa Jelf Eneqvist","doi":"10.1016/j.eururo.2024.04.036","DOIUrl":"10.1016/j.eururo.2024.04.036","url":null,"abstract":"<div><h3>Background and objective</h3><div>In Europe, prostate cancer (PCa) is the most common cancer in men. Screening may therefore be crucial to lower health care costs, morbidity, and mortality. This systematic review aimed to provide a contemporary overview of the costs and benefits of PCa screening programmes.</div></div><div><h3>Methods</h3><div>A peer-reviewed literature search was conducted, using the PICO method. A detailed search strategy was developed in four databases based on the following key search terms: “PCa”, “screening”, and “cost effectiveness”. Any type of economic evaluation was included. The search strategy was restricted to European countries, but no restrictions were set on the year of publication.</div></div><div><h3>Key findings and limitations</h3><div>A total of 7484 studies were identified initially. Of these, 19 studies described the cost effectiveness of PCa screening in Europe. Among the studies using an initially healthy study population, most focussed on risk- and/or age- and/or magnetic resonance imaging (MRI)-based screening in addition to prostate-specific antigen (PSA) testing and compared this with no screening. Incremental cost ratios (ICERs) varied from €5872 per quality-adjusted life year (QALY) to €372 948/QALY, with a median of €56 487/QALY. Risk-based screening followed by MRI testing seemed to be a more cost-effective strategy than no screening.</div></div><div><h3>Conclusions and clinical implications</h3><div>This systematic review indicates that screening programmes incorporating a risk-based approach and MRI have the potential to be cost effective.</div></div><div><h3>Patient summary</h3><div>In this review, we looked at the cost effectiveness of prostate cancer screening in Europe. We found that a risk-based approach and incorporation of magnetic resonance imaging has the potential to be cost effective. However, there remains a knowledge gap regarding cost effectiveness of prostate cancer screening. Therefore, determinants of cost effectiveness require further investigation.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Pages 400-408"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Ivan Mauricio Plata, Julián Azuero, and Valentina García’s Letter to the Editor re: Massimiliano Creta, Giorgio I. Russo, Naeem Bhojani, et al. Bladder Outlet Obstruction Relief and Symptom Improvement Following Medical and Surgical Therapies for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Systematic Review. Eur Urol. 2024;86:315–326","authors":"Massimiliano Creta ,&nbsp;Jean-Nicolas Cornu ,&nbsp;Ferdinando Fusco","doi":"10.1016/j.eururo.2024.07.011","DOIUrl":"10.1016/j.eururo.2024.07.011","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Pages e121-e122"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response","authors":"Nathan M. Merrill ,&nbsp;Samuel D. Kaffenberger ,&nbsp;Liwei Bao ,&nbsp;Nathalie Vandecan ,&nbsp;Laura Goo ,&nbsp;Athena Apfel ,&nbsp;Xu Cheng ,&nbsp;Zhaoping Qin ,&nbsp;Chia-Jen Liu ,&nbsp;Armand Bankhead ,&nbsp;Yin Wang ,&nbsp;Varun Kathawate ,&nbsp;Lila Tudrick ,&nbsp;Habib A. Serhan ,&nbsp;Zackariah Farah ,&nbsp;Chad Ellimoottil ,&nbsp;Khaled S. Hafez ,&nbsp;Lindsey A. Herrel ,&nbsp;Jeffrey S. Montgomery ,&nbsp;Todd M. Morgan ,&nbsp;Aaron M. Udager","doi":"10.1016/j.eururo.2024.05.026","DOIUrl":"10.1016/j.eururo.2024.05.026","url":null,"abstract":"<div><h3>Background and objective</h3><div>Predicting response to therapy for each patient’s tumor is critical to improving long-term outcomes for muscle-invasive bladder cancer. This study aims to establish <em>ex vivo</em> bladder cancer patient–derived organoid (PDO) models that are representative of patients’ tumors and determine the potential efficacy of standard of care and curated experimental therapies.</div></div><div><h3>Methods</h3><div>Tumor material was collected prospectively from consented bladder cancer patients to generate short-term PDO models, which were screened against a panel of clinically relevant drugs in <em>ex vivo</em> three-dimensional culture. Multiomic profiling was utilized to validate the PDO models, establish the molecular characteristics of each tumor, and identify potential biomarkers of drug response. Gene expression (GEX) patterns between paired primary tissue and PDO samples were assessed using Spearman’s rank correlation coefficients. Molecular correlates of therapy response were identified using Pearson correlation coefficients and Kruskal-Wallis tests with Dunn’s post hoc pairwise comparison testing.</div></div><div><h3>Key findings and limitations</h3><div>A total of 106 tumors were collected from 97 patients, with 65 samples yielding sufficient material for complete multiomic molecular characterization and PDO screening with six to 32 drugs/combinations. Short-term PDOs faithfully represent the tumor molecular characteristics, maintain diverse cell types, and avoid shifts in GEX-based subtyping that accompany long-term PDO cultures. Utilizing an integrative approach, novel correlations between <em>ex vivo</em> drug responses and genomic alterations, GEX, and protein expression were identified, including a multiomic signature of gemcitabine response. The positive predictive value of <em>ex vivo</em> drug responses and the novel multiomic gemcitabine response signature need to be validated in future studies.</div></div><div><h3>Conclusions and clinical implications</h3><div>Short-term PDO cultures retain the molecular characteristics of tumor tissue and avoid shifts in expression-based subtyping that have plagued long-term cultures. Integration of multiomic profiling and <em>ex vivo</em> drug screening data identifies potential predictive biomarkers, including a novel signature of gemcitabine response.</div></div><div><h3>Patient summary</h3><div>Better models are needed to predict patient response to therapy in bladder cancer. We developed a platform that uses short-term culture to best mimic each patient’s tumor and assess potential sensitivity to therapeutics.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"86 5","pages":"Pages 434-444"},"PeriodicalIF":25.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142001595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}